共 50 条
IL-1 Family Members in Cancer; Two Sides to Every Story
被引:175
|作者:
Baker, Kevin J.
[1
,2
,3
]
Houston, Aileen
[2
,4
]
Brint, Elizabeth
[1
,4
]
机构:
[1] Univ Coll Cork, Dept Pathol, Cork, Ireland
[2] Univ Coll Cork, Dept Med, Cork, Ireland
[3] Univ Coll Cork, APC Microbiome Ireland, Cork, Ireland
[4] Univ Coll Cork, CancerRes UCC, Cork, Ireland
来源:
FRONTIERS IN IMMUNOLOGY
|
2019年
/
10卷
关键词:
interleukin-1 (IL-1);
inflammation;
cancer;
IL-18;
IL-33;
IL-36 family interleukins;
PREDICTS POOR-PROGNOSIS;
INHIBITS TUMOR-GROWTH;
NATURAL-KILLER-CELLS;
PANCREATIC-CANCER;
OVARIAN-CANCER;
T-CELLS;
DECREASED EXPRESSION;
SERUM INTERLEUKIN-18;
METASTATIC PHENOTYPE;
ACQUIRED-IMMUNITY;
D O I:
10.3389/fimmu.2019.01197
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
The IL-1 family of cytokines currently comprises of seven ligands with pro-inflammatory activity (IL-1 alpha and IL-1 beta, IL-18, IL-33, IL-36 alpha, IL-36 beta, IL-36 gamma) as well as two ligands with anti-inflammatory activity (IL-37, IL-38). These cytokines are known to play a key role in modulating both the innate and adaptive immunes response, with dysregulation linked to a variety of autoimmune and inflammatory diseases. Given the increasing appreciation of the link between inflammation and cancer, the role of several members of this family in the pathogenesis of cancer has been extensively investigated. In this review, we highlight both the pro- and anti-tumorigenic effects identified for almost all members of this family, and explore potential underlying mechanisms accounting for these divergent effects. Such dual functions need to be carefully assessed when developing therapeutic intervention strategies targeting these cytokines in cancer.
引用
收藏
页数:16
相关论文